National Bank of Canada’s Sunshine Biopharma SBFM Stock Holding History

National Bank of Canada’s Portfolio SBFM Stock Details SBFM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$10	Buy	5 +4	+400%	+$26	﹤0.01%	3097
2026 Q1	$9	Hold	1	–	–	﹤0.01%	2910
2025 Q4	$12	Hold	1	–	–	﹤0.01%	2851
2025 Q3	$15	Hold	1	–	–	﹤0.01%	2810
2025 Q2	$14	Hold	1	–	–	﹤0.01%	2937
2025 Q1	$19	Hold	1	–	–	﹤0.01%	2777
2024 Q4	$21	Hold	1	–	–	﹤0.01%	2853
2024 Q3	$22	Buy	+1	New	+$43	﹤0.01%	2639
2024 Q2	–	Hold	0	–	–	–	2665
2024 Q1	–	Hold	0	–	-$1.63K	–	2894
2023 Q4	–	Hold	0	–	–	–	2484
2023 Q3	–	Hold	0	–	–	–	2516
2023 Q2	–	Hold	0	–	–	–	2429
2023 Q1	–	Hold	0	–	–	–	2329
2022 Q4	–	Hold	0	–	–	–	2382
2022 Q3	–	Hold	0	–	–	–	2623
2022 Q2	–	Hold	0	–	–	–	2714
2022 Q1	–	Hold	0	–	–	–	2665

Other funds holding SBFM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

CIAM

Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

SFG

Strive Financial Group Carmel, Indiana $230M AUM

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

National Bank of Canada's SBFM Position: Q2 2026 in Review

National Bank of Canada increased its Sunshine Biopharma (SBFM) stake by 400% in Q2 2026, buying an estimated $26 and bringing the position to 5 shares worth $10. The position accounts for ﹤0.01% of the portfolio, ranked #3097.

National Bank of Canada first reported a position in SBFM in Q3 2024 and has held it in 8 quarters since. The position peaked at $22 in Q3 2024. 9 funds tracked by Wall St. Rank hold SBFM as of Q2 2026.

National Bank of Canada held 5 shares of Sunshine Biopharma worth $10 as of Q2 2026.
National Bank of Canada bought 4 Sunshine Biopharma shares in Q2 2026, an estimated $26.
Sunshine Biopharma made up ﹤0.01% of National Bank of Canada's portfolio in Q2 2026, its #3097 holding.
National Bank of Canada first reported a position in Sunshine Biopharma in Q3 2024 and has held it in 8 quarters since.
National Bank of Canada's Sunshine Biopharma position peaked at $22 in Q3 2024.
9 funds tracked by Wall St. Rank held Sunshine Biopharma as of Q2 2026.

Based on National Bank of Canada's 13F filing for Q2 2026, filed 10 Aug 2026.